Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

PHASE2CompletedINTERVENTIONAL
Enrollment

448

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions
Rabies
Interventions
BIOLOGICAL

SYN023

it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible

BIOLOGICAL

HRIG (HyperRab)

it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible

BIOLOGICAL

Rabies vaccine

it should be administered in deltoid muscle

Trial Locations (14)

1000

Manila Doctors Hospital Institutional Review Board, Manila

1118

Far Eastern University Hospital Nicanor Reyes Medical Foundation, Quezon City

1780

Asian Hospital and Medical Center, Muntinlupa

1781

Center of Excellence in Drug Research, Evaluation and Studies, Inc., Muntinlupa

Research Institute For Tropical Medicine, Muntinlupa

2600

Baguio General Hospital and Medical Center, Baguio City

4114

De La Salle Health Sciences Institute Independent Ethics Committee, Cavite City

8000

Southern Philippines Medical Center, Davao City

22903

University of Virginia, Charlottesville

32610

University of Florida, Gainesville

38358

Clinical Research Solutions PC -Milan, Milan

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

Unknown

Mary Johnston Hospital, Manila

All Listed Sponsors
collaborator

Synermore Biologics USA Limited

UNKNOWN

lead

Synermore Biologics Co., Ltd.

INDUSTRY

NCT03961555 - Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies | Biotech Hunter | Biotech Hunter